|93.53||-0.6200||-0.66%||Vol 155.48K||1Y Perf 180.40%|
|Apr 23rd, 2021 10:38 DELAYED|
|- -%||- -|
|Target Price||115.80||Analyst Rating||Strong Buy 1.06|
|Potential %||23.88||Finscreener Ranking||★★★★+ 58.22|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★+ 53.87|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 75.52|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Market Cap||20.96B||Earnings Rating||Sell|
|Price Range Ratio 52W %||95.26||Earnings Date||5th May 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||5th May 2021|
|Estimated EPS Next Report||0.19|
|EPS Growth Next 5 Years %||14.00|
|Avg. Weekly Volume||994.18K|
|Avg. Monthly Volume||1.53M|
|Avg. Quarterly Volume||1.89M|
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP) stock closed at 94.15 per share at the end of the most recent trading day (a 0.64% change compared to the prior day closing price) with a volume of 1.11M shares and market capitalization of 20.96B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 1395 people. Horizon Therapeutics Public Limited Company CEO is Timothy P. Walbert.
The one-year performance of Horizon Therapeutics Public Limited Company stock is 180.4%, while year-to-date (YTD) performance is 28.71%. HZNP stock has a five-year performance of 474.44%. Its 52-week range is between 33.05 and 96.54, which gives HZNP stock a 52-week price range ratio of 95.26%
Horizon Therapeutics Public Limited Company currently has a PE ratio of 55.50, a price-to-book (PB) ratio of 5.19, a price-to-sale (PS) ratio of 10.97, a price to cashflow ratio of 36.10, a PEG ratio of 2.32, a ROA of 7.15%, a ROC of 21.80% and a ROE of 12.17%. The company’s profit margin is 22.42%, its EBITDA margin is 29.90%, and its revenue ttm is $1.84 Billion , which makes it $8.23 revenue per share.
Of the last four earnings reports from Horizon Therapeutics Public Limited Company, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.19 for the next earnings report. Horizon Therapeutics Public Limited Company’s next earnings report date is 05th May 2021.
The consensus rating of Wall Street analysts for Horizon Therapeutics Public Limited Company is Strong Buy (1.06), with a target price of $115.8, which is +23.88% compared to the current price. The earnings rating for Horizon Therapeutics Public Limited Company stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Horizon Therapeutics Public Limited Company has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Horizon Therapeutics Public Limited Company has a Buy technical analysis rating based on Technical Indicators (ADX : 14.32, ATR14 : 4.16, CCI20 : 100.97, Chaikin Money Flow : 0.12, MACD : 2.09, Money Flow Index : 57.21, ROC : 4.62, RSI : 56.02, STOCH (14,3) : 77.96, STOCH RSI : 1.00, UO : 54.04, Williams %R : -22.04), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Horizon Therapeutics Public Limited Company in the last 12-months were: Andy Pasternak (Option Excercise at a value of $0), Barry J. Moze (Option Excercise at a value of $461 918), Barry J. Moze (Sold 166 271 shares of value $13 219 747 ), Brian K. Beeler (Option Excercise at a value of $419 666), Brian K. Beeler (Sold 90 724 shares of value $4 933 814 ), Daniel A. Camardo (Option Excercise at a value of $442 093), Daniel A. Camardo (Sold 16 400 shares of value $1 371 670 ), Geoffrey M. Curtis (Option Excercise at a value of $1 050 710), Geoffrey M. Curtis (Sold 92 657 shares of value $7 707 706 ), Gino Santini (Option Excercise at a value of $206 523), Gino Santini (Sold 12 000 shares of value $1 097 600 ), Irina P. Konstantinovsky (Option Excercise at a value of $1 140 087), Irina P. Konstantinovsky (Sold 103 481 shares of value $5 841 265 ), James S. Shannon (Option Excercise at a value of $88 158), James S. Shannon (Sold 7 232 shares of value $660 261 ), Jeff W. Himawan (Option Excercise at a value of $0), Jeffrey D. Kent (Option Excercise at a value of $215 980), Jeffrey D. Kent (Sold 50 729 shares of value $3 918 482 ), Jeffrey W. Sherman (Option Excercise at a value of $264 986), Jeffrey W. Sherman (Sold 146 421 shares of value $9 405 018 ), Michael DesJardin (Option Excercise at a value of $789 060), Michael DesJardin (Sold 92 313 shares of value $6 463 856 ), Michael G. Grey (Option Excercise at a value of $242 254), Michael G. Grey (Sold 46 590 shares of value $3 042 318 ), Miles W. Mchugh (Option Excercise at a value of $0), Miles W. Mchugh (Sold 117 012 shares of value $5 540 173 ), Pascale Witz (Option Excercise at a value of $0), Paul W. Hoelscher (Option Excercise at a value of $0), Paul W. Hoelscher (Sold 134 570 shares of value $6 230 473 ), Susan Mahony (Option Excercise at a value of $0), Thomas H. Watkins (Option Excercise at a value of $0), Timothy P. Walbert (Option Excercise at a value of $0), Timothy P. Walbert (Sold 359 502 shares of value $27 759 357 ), Vikram Karnani (Option Excercise at a value of $483 636), Vikram Karnani (Sold 132 612 shares of value $6 393 635 ), William F. Daniel (Option Excercise at a value of $0)
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.